MARKET

CLVS

CLVS

Clovis Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.969
-0.051
-1.02%
Opening 12:15 07/23 EDT
OPEN
5.03
PREV CLOSE
5.02
HIGH
5.04
LOW
4.900
VOLUME
1.75M
TURNOVER
--
52 WEEK HIGH
11.10
52 WEEK LOW
4.080
MARKET CAP
519.58M
P/E (TTM)
-1.3443
1D
5D
1M
3M
1Y
5Y
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2021 financial results on Wednesday, August 4, 2021, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30am E...
Business Wire · 2d ago
Bender Robert & Associates Buys Alphabet Inc, Advanced Micro Devices Inc, Sells Alphabet ...
GuruFocus News · 6d ago
Thinking about buying stock in Cinedigm, VEON, Alcoa, Clovis Oncology, or Skillz?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CIDM, VEON, AA, CLVS, and SKLZ.
PR Newswire - PRF · 07/16 15:15
Thinking about buying stock in Ashford Hospitality Trust, Clovis Oncology, Exela Technologies, Wipro, or Atossa Therapeutics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AHT, CLVS, XELA, WIT, and ATOS.
PR Newswire - PRF · 07/14 13:31
VLDR, CLVS, WATT among pre-market gainers
Oxbridge (OXBR) +57%.Jiuzi (JZXN) +37%.Yunhong CTI (CTIB) +23%.AgriFORCE Growing  (AGRI) +14%.Scienjoy  (SJ) +12%.Qualigen Therapeutics (QLGN) +7%.Powerbridge (PBTS) +9%.China Online Edducation (COE) +8%.Clovis Oncology (CLVS) +8%.Forward Pharma (FWP) +8%....
Seekingalpha · 07/14 12:32
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 07/14 12:08
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Investor Place · 07/14 11:33
26 Stocks Moving in Wednesday's Pre-Market Session
Gainers Yunhong CTI Ltd. (NASDAQ: CTIB) shares rose 35.6% to $3.54 in pre-market trading after jumping around 12% on Tuesday.
Benzinga · 07/14 11:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLVS. Analyze the recent business situations of Clovis Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLVS stock price target is 6.35 with a high estimate of 12.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 281
Institutional Holdings: 58.23M
% Owned: 55.69%
Shares Outstanding: 104.56M
TypeInstitutionsShares
Increased
44
6.24M
New
40
1.46M
Decreased
43
7.89M
Sold Out
31
4.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.25%
Pharmaceuticals & Medical Research
+0.64%
Key Executives
Non-Executive Chairman/Independent Director
Ginger Graham
President/Chief Executive Officer/Co-Founder/Director
Patrick Mahaffy
Co-Founder/Executive Vice President
Gillian Ivers - Read
Chief Financial Officer/Executive Vice President
Daniel Muehl
Executive Vice President/Chief Scientific Officer
Thomas Harding
Executive Vice President/General Counsel
Paul Gross
Executive Vice President/Director of Human Resources
Ann Bozeman
Executive Vice President
Lindsey Rolfe
Independent Director
Brian Atwood
Independent Director
Robert Azelby
Independent Director
James Blair
Independent Director
Richard Fair
Independent Director
Keith Flaherty
Independent Director
Paul Klingenstein
Independent Director
Edward Mckinley
Independent Director
Ronit Simantov
Independent Director
Thorlef Spickschen
No Data
  • All
  • Financials
  • Insiders
More
About CLVS
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Webull offers kinds of Clovis Oncology Inc stock information, including NASDAQ:CLVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLVS stock methods without spending real money on the virtual paper trading platform.